<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01782911</url>
  </required_header>
  <id_info>
    <org_study_id>MAD-IO-01-2013-01</org_study_id>
    <nct_id>NCT01782911</nct_id>
  </id_info>
  <brief_title>Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients</brief_title>
  <acronym>RES-IVF</acronym>
  <official_title>Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Undergoing IVF Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is characterized by enlarged ovaries, menstrual irregularity&#xD;
      and hyperandrogenism and is the most common cause of oligoovulatory infertility. Insulin&#xD;
      resistance with resulting hyperinsulinemia is also common among women with PCOS, along with&#xD;
      increased risk for dyslipidemia, hypertension, diabetes and related cardiovascular&#xD;
      consequences. Resveratrol is a natural polyphenol with anti-carcinogenic, anti-proliferative&#xD;
      and pro-apoptotic properties, that has been shown to decrease proliferation and&#xD;
      steroidogenesis in theca cells, emerging as a potential therapeutic agent in PCOS patients.&#xD;
      However, little is known about its potential beneficial effect on oocyte quality as well as&#xD;
      other reproductive outcomes, such as implantation an pregnancy rates. The present study&#xD;
      evaluates effects of resveratrol on selected biochemical parameters and reproductive outcome&#xD;
      among patients with PCOS who undergo in vitro fertilization (IVF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2013</start_date>
  <completion_date type="Actual">February 1, 2013</completion_date>
  <primary_completion_date type="Actual">February 1, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of resveratrol on oocyte quality</measure>
    <time_frame>40 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of resveratrol on testosterone levels.</measure>
    <time_frame>40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of resveratrol on inflammatory markers</measure>
    <time_frame>40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of resveratrol on the fertilization rate.</measure>
    <time_frame>40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of resveratrol on the pregnancy rate.</measure>
    <time_frame>40 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Androgen Profile</condition>
  <condition>Inflammatory Markers</condition>
  <condition>IVF Outcome</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>The patients will take 2 g of resveratrol per day for 40 days.</description>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo pills</intervention_name>
    <description>The patients will take placebo for 40 days.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged from 18 to 40 years old.&#xD;
&#xD;
          -  PCOS diagnosis (according to Rotterdam criteria).&#xD;
&#xD;
          -  Mild or moderate male factor, tubal factor or unknown infertility.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Follicle stimulation hormone (third of day of menstruation) &gt; 10 milli international&#xD;
             units/L.&#xD;
&#xD;
          -  Endometriosis (III o IV).&#xD;
&#xD;
          -  Congenital adrenal hyperplasia.&#xD;
&#xD;
          -  Cushing syndrome.&#xD;
&#xD;
          -  Hyperprolactinemia.&#xD;
&#xD;
          -  Thyroid disease.&#xD;
&#xD;
          -  Androgenic hormone secretor tumors.&#xD;
&#xD;
          -  Patients included in this trial did not take either oral contraceptives, steroids or&#xD;
             other medications that could modify the ovarian function, insulin sensitivity or lipid&#xD;
             metabolism 3 months before the onset of the trial.&#xD;
&#xD;
          -  Severe male factor (sperm concentration &lt; 5 mill/ml).&#xD;
&#xD;
          -  Patients undergoing oocyte vitrification to avoid hyperstimulation syndrome will be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ivi Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 28, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Madrid</investigator_affiliation>
    <investigator_full_name>Juan A Garcia-Velasco</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Androgen</keyword>
  <keyword>IVF</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>PCOS.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

